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Abstract 
Aims/Hypothesis: Studies in permanent neonatal diabetes suggest that sulphonylureas 
lower blood glucose without causing hypoglycemia, in part by augmenting the incretin 
effect. This mechanism has not previously been attributed to sulphonylureas in patients 
with type 2 diabetes (T2DM). We therefore aimed to evaluate the impact of low-dose 
gliclazide on beta-cell function and incretin action in patients with T2DM.
Methods: Paired oral glucose tolerance tests and isoglycemic infusions were performed 
to evaluate the difference in the classical incretin effect in the presence and absence 
of low-dose gliclazide in 16 subjects with T2DM (hemoglobin A1c < 64 mmol/mol, 8.0%) 
treated with diet or metformin monotherapy. Beta-cell function modeling was undertaken 
to describe the relationship between insulin secretion and glucose concentration.
Results: A single dose of 20 mg gliclazide reduced mean glucose during the oral glucose 
tolerance test from 12.01 ± 0.56 to 10.82 ± 0.5mmol/l [P = 0.0006; mean ± standard error 
of the mean (SEM)]. The classical incretin effect was augmented by 20 mg gliclazide, 
from 35.5% (lower quartile 27.3, upper quartile 61.2) to 54.99% (34.8, 72.8; P = 0.049). 
Gliclazide increased beta-cell glucose sensitivity by 46% [control 22.61 ± 3.94, gliclazide 
33.11 ± 7.83 (P = 0.01)] as well as late-phase incretin potentiation [control 0.92 ± 0.05, 
gliclazide 1.285 ± 0.14 (P = 0.038)].
Conclusions/Interpretation: Low-dose gliclazide reduces plasma glucose in response to 
oral glucose load, with concomitant augmentation of the classical incretin effect. Beta-
cell modeling shows that low plasma concentrations of gliclazide potentiate late-phase 
insulin secretion and increase glucose sensitivity by 50%. Further studies are merited 
to explore whether low-dose gliclazide, by enhancing incretin action, could effectively 
lower blood glucose without risk of hypoglycemia.
Key Words: sulphonylureas, gliclazide, incretins, incretin effect, beta-cell physiology, type 2 diabetes, KATP channel, 







/article/106/7/2036/6162832 by guest on 05 July 2021
The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 7 2037
The incretin effect is defined as amplification of insulin 
secretion following oral glucose as opposed to the same 
stimulus given intravenously to provide identical plasma 
glucose concentrations; this is due to the postprandial in-
sulin response being mediated by the release of incretin 
hormones from the gastrointestinal tract (1). The incretin 
effect is diminished or absent in type 2 diabetes mellitus (1), 
related to the diminished insulinotropic effect of glucose‐
dependent insulinotropic polypeptide (GIP) (2,3). The loss 
of the incretin effect is targeted therapeutically by inhibiting 
breakdown of GIP and glucagon‐like peptide 1 (GLP-1) 
via dipeptidyl-peptidase 4 or by use of supraphysiological 
doses of GLP-1 receptor agonists.
Insulin secretion from the pancreatic beta-cell is con-
trolled by 2 interacting pathways: the triggering pathway 
and the amplifying pathway (4), with the amplifying 
pathway requiring the triggering pathway to be effective. 
Sulphonylureas act by stimulating glucose-independent 
insulin secretion via closure of adenosine 5′-triphosphate-
sensitive potassium (KATP) channels (5), thereby activating 
the triggering pathway. In contrast, incretins and drugs 
augmenting the incretin pathway activate the amplifying 
pathway, resulting in glucose-dependent insulin secre-
tion. A key defect in type 2 diabetes lies in the amplifying 
pathway (6); however, the role of the triggering pathway 
in the defective incretin effect seen in type 2 diabetes is 
uncertain.
Patients with neonatal diabetes due to activating mu-
tations in the genes encoding the Katp channel provide po-
tential insight into the role of the triggering pathway and 
potential interaction with incretin action (7-10). Patients 
with these forms of neonatal diabetes can effectively tran-
sition off insulin onto high-dose sulphonylurea, and most 
achieve normoglycemia with no hypoglycemia, consistent 
with glucose-dependent insulin secretion (11). In physio-
logical studies on these patients before and after use of 
sulphonylureas, there was only minimal increase in insulin 
secretion by sulphonylureas following intravenous glucose, 
yet a robust insulin secretory response was seen with an 
oral glucose stimulus consistent with sulphonylureas aug-
menting the incretin effect (11). Mechanistically, this can be 
explained as follows: in the absence of sulphonylureas, the 
activating mutations in the KATP channel result in the chan-
nels being insensitive to changes in intracellular adenosine 
5′-triphosphate:adenosine 5′-diphospate, and so the beta-
cell membrane remains hyperpolarized and the beta-cells 
are unable to secrete insulin (ie, the triggering pathway is 
blocked); with high-dose sulphonylurea treatment, there is 
closure of some of the KATP channels, sufficient to enable 
incretins to augment secretion but with only minimal acti-
vation of the triggering pathway. In parallels with neonatal 
diabetes, alteration in Katp channel function also plays an 
etiological role in the development of type 2 diabetes with 
the E23K/S1119 KCNJ11/ABCC8 variants associated with 
a 1.32 increase in the risk of type 2 diabetes (12). Thus, 
similar, if less extreme, mechanisms may be seen in patients 
with type 2 diabetes.
We hypothesized that, like patients with neonatal dia-
betes, sulphonylureas might be able to promote incretin 
action with little or no direct effect on insulin secretion if 
used at a low enough dose in type 2 diabetes. Therefore, we 
have evaluated the incretin effect using the gold standard 
protocol of paired frequently sampled oral glucose toler-
ance tests (OGTT) and matched isoglycemic intravenous 
glucose infusions (IIGI) in patients with type 2 diabetes 
treated with acute low-dose sulphonylurea, a condition 
that does not stimulate insulin secretion markedly.
Materials and Methods
Recruitment
We utilized the Scottish Diabetes Research Network and 
SHARE network permissions to recruit 20 participants 
with type 2 diabetes mellitus controlled with no treat-
ment or metformin monotherapy with hemoglobin A1c 
(HbA1c) < 64  mmol/mol (8.0%) aged between 40 and 
80 years with estimated glomerular filtration rate ≥ 50 mL/
min−1 and alanine aminotransferase ≤ 2.5 times the upper 
limit of normal. The study recruited only white British par-
ticipants to avoid heterogeneity within the study. Exclusion 
criteria included inability to consent, type 1 diabetes mel-
litus, anemia (hemoglobin < 12.0 g/dL for women, <13.0 g/
dL for men), significant renal or hepatic impairment, preg-
nancy, lactation or female planning to conceive within the 
study period, established pancreatic disease, or any other 
significant reason as determined by the investigators.
Study design
Research involved a single site, parallel, proof-of-concept 
physiological study at the Clinical Research Centre at 
Ninewells Hospital (Dundee, UK). Ethical approval 
was obtained from the East of Scotland Research Ethics 
Committee (18/ES/0064) and the study was registered 
with ClinicalTrials.gov (NCT03705195). All research 
was conducted in accordance with the Declaration of 
Helsinki, and written informed consent was obtained 
for all participants prior to study inclusion. Participants 
were informed of the purpose of study as part of in-
formed consent. Participants attended the research center 
for 5 separate visits.
An initial screening visit assessed eligibility and obtained 
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medical history and examination were performed. Baseline 
vital signs, anthropometry, full blood count, urea and elec-
trolytes, and baseline HbA1c were completed to confirm 
safety and eligibility.
The study design (Fig. 1) comprised a 4-h frequently 
sampled 75-g OGTT visit, followed on a separate day by 
a 4-h IIGI to mimic the plasma glucose curve obtained 
during the OGTT by means of an adjustable intravenous 
20% glucose infusion. In the first 2 intervention visits 
(visits 2 and 3), a control OGTT, followed on a separate 
day by a control IIGI, were performed. At the next 2 
visits (visits 4 and 5), oral liquid low-dose gliclazide was 
administered 1 h before an OGTT and, on a separate 
day, an IIGI. Study visits took place 1 week apart over 
a period of 4 weeks. Participants on prior metformin 
monotherapy omitted their dose on the morning of each 
visit to avoid postdose peak concentrations occurring 
during intervention.
Study phases
To identify the most effective dose of gliclazide, the study 
was conducted in 2 phases. An exploratory first, dose-
ranging phase (n = 8) was conducted that randomly allo-
cated participants to receive either 10 mg (n = 4) or 20 mg 
(n = 4) of gliclazide. Phase 1 was unblinded but randomized 
in accordance with General Medical Council Good Clinical 
Practice utilizing computer-generated randomization con-
ducted by the principal investigator (Research Randomizer, 
www.randomizer.org). Interim analysis was conducted 
following phase 1 to identify whether a 10-mg or 20-mg 
dose of gliclazide was more effective. The dose with greater 
effect was used in further (n = 12) participants in phase 2.
Oral glucose tolerance test
Total test time was 240 min; liquid gliclazide was given 
1 h prior to gliclazide intervention visits. Participants at-
tended the Clinical Research Centre following a 10-h fast. 
A single intravenous cannula was sited in the participant’s 
antecubital fossa for blood collection. At time 0, participants 
consumed a drink containing 75 g of anhydrous glucose 
(133 mL Nutricia Polycal Liquid, Nutricia Limited, UK) di-
luted to 300 mL with water over a maximum 5-min period.
To enable glucose matching, bedside blood glucose level 
was analyzed at 5-min intervals in the first hour of study, 
10 min in the second hour, and every 15 min in the final 2 h 
(Biosen GP+, EKF Diagnostics, Cardiff, UK). Blood samples 
were drawn at defined time-points for insulin, C-peptide, 
glucagon, glucose: 0, 5, 10, 15, 20, 30, 40, 45, 50, 60, 70, 
90, 120, 150, 180, and 240 min. Total GLP-1 and GIP were 
measured over the same time course but during the OGTT 
only. In the intervention visits, gliclazide suspension (80 
mg/5 mL gliclazide suspension, Alliance Pharmaceuticals, 
UK) was administered 60 min prior to oral glucose admin-
istration. Gliclazide concentration was sampled at 30-min 
intervals throughout visits 4 and 5.
Isoglycemic intravenous glucose infusion
The IIGI protocol was obtained from the Steno Diabetes 
Center at Gentofte Hospital, Copenhagen, Denmark. An 
adjustable infusion of 20% glucose (Fresenius Kabi Ltd) 
was infused via infusion pump (Infusomat Space, B. Braun 
Medical, Sheffield, UK) according to bedside measure-
ments of plasma glucose (13). Blood sampling and bedside 
measurements were performed in identical time course to 
OGTT. Further bedside sampling was occasionally required 
to maintain isoglycemia.
Bedside glucose analysis
Bedside glucose analysis was performed utilizing the Biosen 
C-line GP+ (EKF Diagnostics, Cardiff, UK). Whole venous 
blood was taken up with a 20  µL end-to-end capillary, 
hemolyzed, and diluted in microtest tube, prefilled with a 
hemolyzing solution and then measured by the device via 
enzymatic-amperometry and chip-sensor technology. The 
system was set to correct and calibrate for use of whole-
blood sampling. The accuracy of the isoglycemic clamp was 
confirmed after each experimental visit with formal blood 
glucose analysis.
Gliclazide suspension
Gliclazide 80 mg/5 mL suspension was sourced through 
Alliance Pharmaceuticals. Respective 10-mg or 20-mg 
doses were administered orally via microdosing syringe.
Blood collection
All blood collection was performed utilizing BD Vacutainer 
systems. Samples for insulin, C-peptide, glucagon, and 
Figure 1. Study design comprising paired OGTT and IIGI in the pres-
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gliclazide analysis were collected for EDTA plasma. 
Samples for glucose were collected in fluoride oxalate and 
collection for incretin analysis were obtained utilizing P800 
blood collection system containing K2EDTA and protease 
inhibitors. Samples were iced following collection and cen-
trifuged immediately in accordance with recommended 
guidance from receiving laboratories.
Glucose solution for oral glucose tolerance test
Glucose solution for OGTT was prepared utilizing Nutricia 
Polycal liquid. One hundred thirteen milliliters of Polycal 
Liquid is equivalent to 75 g of anhydrous glucose, which 
was made up to a total volume of 300 mL with water as per 
standard NHS Tayside OGTT protocol.
Laboratory analyses
Insulin and C-peptide
Analysis of insulin and C-peptide was performed 
by Clinical Chemistry, Royal Devon and Exeter 
Hospital—602 modules Cobas 8000 automated plat-
form using sandwich chemiluminescence immunoassay 
(Elecsys insulin).
Glucose
Glucose analysis was performed by NHS Tayside 
Blood Sciences at Ninewells Hospital utilizing Siemens 
ADVIA Chemistry, Glucose Hexokinase_3 Concentrated 
Reagents.
Glucagon
Glucagon analysis was performed by the Immunoassay 
Core Biomarker Laboratory, University of Dundee, util-
izing EMD Millipore glucagon radioimmunoassay kit 
(Merck, Billerica, MA, USA).
Incretins
Total GLP-1 and GIP analyses were performed by the 
Immunoassay Core Biomarker Laboratory, University of 
Dundee, utilizing MSD metabolic assay total GLP-1 and 
GIP assay kits.
Gliclazide
Gliclazide analysis was performed by the Biomarker 
and Drug Analysis Core Facility, University of Dundee 
utilizing a uniquely developed gliclazide quantification 
method in human plasma by liquid chromatography 
with tandem mass spectrometry, high-performance liquid 
chromatography separation, and tandem mass spectrom-
etry analysis.
Data and statistical analyses
Area under curve
The incremental area under the curve (AUC) for insulin and 
C-peptide were derived via the trapezoidal method for each 
intervention visit.
Incretin effect
The incretin effect was defined as the percentage increase in 
insulin secretion between oral and intravenous glucose. The 
classical incretin effect for control and intervention visits 
were calculated utilizing the following formula (1,14,15):
Incretin Effect (%) = 100× (iAUCOGTTiAUCIIGI)
iAUCOGTT
Study outcomes
The primary outcome was the difference in the classical 
incretin effect between control and low-dose gliclazide 
treatment. Beta-cell function derived from modeling was 
evaluated as a secondary outcome (16,17).
Power
The power for study was determined via a related study 
design utilizing hyperglycemic clamps and intravenous 
incretins. The study by Aaboe et  al (18) involved hyper-
glycemic clamps on 12 subjects with an effect size of 
~1.05 with 80% power, and a P-value < 0.01 to detect a 
difference of adding sulphonylurea to GIP. In this study, 
physiological concentrations of endogenous incretins were 
anticipated, and lower doses of sulphonylurea were used, 
thus 20 participants were recruited. The participants from 
phase 1 receiving the gliclazide stimulus resulting in the 
largest augmentation of the incretin effect (n = 4) were in-
cluded in the results analysis with phase 2 participants to 
total 16 for study. Allowing for 2 noncompleters, 14 par-
ticipants studied provided 80% power with a significance 
level of 0.05 to detect an increase over the GLP-1 response 
of 70% or more observed by Aaboe et al. A P-value < 0.05 
was considered statistically significant.
Data presentation
The observed difference in incretin effect for both in-
sulin and C-peptide were compared using a Wilcoxon 
signed-rank test. As the data were not normally dis-
tributed, results are presented as median (lower quar-
tile, upper quartile) unless otherwise stated: results for 
total GLP-1, GIP, and glucagon were also compared 
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gliclazide, being normally distributed, were analyzed 
utilizing paired t-test; mean values were calculated as 
AUC over time during the OGTT, and results are pre-
sented as mean ± SEM.
Modeling
The incretin effect was also assessed using a previously de-
scribed model, derived from (17,19) and designed to ana-
lyze the OGTT and IIGI test simultaneously. The model 
postulates that during the OGTT incretins potentiate in-
sulin secretion by stimulating early insulin release and 
enhancing the beta-cell dose-response relationship, which 
relates insulin secretion to the concomitant glucose con-
centration. The main model parameters are glucose sensi-
tivity (ie, the mean slope of beta-cell dose-response curve 
during IIGI); rate sensitivity (representing early insulin re-
lease (20,21) from IIGI and from OGTT); glucose-induced 
potentiation, representing a time-dependent modulation 
of dose-response during IIGI; and incretin potentiation, 
quantifying the time course of the incretin effect. The mean 
incretin effect during the whole OGTT or in the late period 
was calculated as AUC/time of incretin potentiation. Insulin 
secretion (pmol min−1 m−2) was also calculated, as well as 
its AUC over IIGI or OGTT (nmol/m2). Data are presented 
as mean ± SEM.
Testing and software
Statistical analyses were conducted through GraphPad 




Study recruitment ran from July 2018 to April 2019. 
In total, 24 participants were screened for study. Four 
exclusions were made due to anemia (n = 1), suboptimal 
HbA1c (n = 2), and comorbidity as deemed by investiga-
tors (n = 1). All participants recruited (n = 20) gave in-
formed written consent and completed the study. The 
baseline characteristics of the study participants are pro-
vided in Table 1. The most common concomitant medica-
tion included statins (n = 12), anti-hypertensives (n = 11), 
and proton-pump inhibitors (n = 6).
Determination of dose
In the exploratory dose-ranging phase, mean glucose was 
reduced in all participants following low-dose gliclazide 
intervention, without incidence of hypoglycemia; however, 
this effect was greater in the 20-mg cohort (mean ± SEM: 
control 11.3 ± 1.6 mmol/L, gliclazide 10.13 ± 1.4 mmol/L; 
P = 0.018) vs the 10-mg cohort (mean ± SEM: con-
trol 11.65 ± 1.2  mmol/L, gliclazide 11.03 ± 1.5  mmol/L; 
P = 0.36). Therefore, the 20-mg dose was chosen for the 
phase 2.  In this small cohort, neither dose exhibited aug-
mentation of the classical incretin effect of insulin or 
C-peptide (Table 2).
Glycemic response
Twenty milligrams of gliclazide given 1 h before 
the OGTT lowered mean glucose level during the 
OGTT (mean ± SEM: control 12.01 ± 0.56  mmol/L, 
gliclazide 10.82 ± 0.5  mmol/L; P = 0.0006) (Table 3) 
as well as the mean basal glucose (mean ± SEM: con-
trol 7.3 ± 0.28  mmol/L, gliclazide 6.8 ± 0.291  mmol/L; 
P = 0.004). The OGTT-IIGI were well matched (Fig. 2A).
Insulin, C-peptide, and the incretin effect
Insulin and C-peptide profiles are presented in Fig. 2C and 
2D. Table 3 summarizes incretin effect measures derived 
from AUC values. AUC values are provided in Table 4. 
The classical incretin effect estimates, as percentages, were 













Duration of  
diabetes (years)
Age at diagnosis 
(years)
Full study 20 8/12 10/10 69.5 (9.25) 32.0 (7.8) 50.9 (19) 8 (5.5) 60.5 (7.7)
Phase 1 10 
mg
4 2/2 2/2 66.0 (14) 39.7 (7.8) 54.0 (12.3) 10.5 (5.5) 54.5 (10)
Phase 2 20 
mg
4 2/2 2/2 70.0 (13) 37.9 (10.2) 45.5 (8.5) 9.0 (6.5) 60.5 (6.3)
Phase 2 16 6/10 8/8 69.5 (10) 32.0 (5.4) 50.0 (7) 8.0 (5.5) 61.0 (5.5)
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increased by 20 mg gliclazide compared to control [median 
(LQ, UQ)]: incretin effect-INSULIN [control 35.5 (27.3, 62.1), 
gliclazide 54.99 (34.8, 72.8); P = 0.049], incretin effectc-
peptide [control 28.4 (12.9, 47.0), gliclazide 39.9 (17.9, 52.8); 
P = 0.049]. When the mean glucose of each participant was 
regressed against mean insulin, with and without gliclazide, 
significant augmentation was shown in the slope of insulin 
secretion in response to oral glucose following gliclazide 
treatment (control 33.6 vs gliclazide 80.97; P < 0.001) (Fig. 
3A). The slope also increased, but to lesser extent, in the 
intravenous visits (control 13.63, gliclazide 25.2; P = 0.03) 
(Fig. 3B). There was no difference in incretin effect de-
pendent on baseline gender, HbA1c, pre-existing diabetes 
treatment, or duration of diabetes.
Modeling of beta-cell function and the incretin 
effect
Insulin secretion rates for OGTT and IIGI in the 2 treat-
ment groups were similar, with an apparent sustained 
incretin effect in late stages of OGTT (Fig. 4). The beta-
cell function parameters derived from modeling of beta-cell 
function are shown in Table 5. Beta-cell glucose sensi-
tivity (mean ± SEM; calculated from IIGI) increased from 
22.61 ± 3.94 in the control to 33.11 ± 7.83 (P = 0.01) by 
gliclazide. The incretin potentiation factor overall was no 
different between control and gliclazide treatment, but 
there was an increase in late-phase incretin potentiation 
with an increase in AUC/time from 180 to 210 min (Fig. 5).
Glucagon, GLP-1, and GIP
Glucagon secretion was unaffected by the presence of 
gliclazide in OGTT [mean ± SEM: AUCGLUCAGON control 
4.9 (4.5, 5.6) nmol l−1min−1, gliclazide 4.9 (4.4, 5.8) nmol 
l−1min−1; P = 0.56]. There was no impact of gliclazide on 
the time course of total GLP-1 or GIP as well as AUC. 
AUCTotalGLP-1 [mean ± SEM: control 1.04 (0.9, 1.5) nmol 
l−1min−1, gliclazide 1.0 (0.7, 1.8) nmol l−1min−1; P = 0.2524] 
and AUCTOTALGIP (mean ± SEM: control 15.06 (9.1, 19.3) 
nmol l−1min−1, gliclazide 13.6 (11.6, 19.9) nmol l−1min−1; 
P = 0.51] (Table 4).
Gliclazide pharmacokinetics
The time course of gliclazide concentration is shown in 
Figure 2B. The mean gliclazide concentrations from AUC 
were 681.2 ± 83.5 ng/mL for OGTT and 742.2 ± 85.5 
ng/mL for IIGI (P = 0.12), respectively. Some difference 
was noted in gliclazide concentrations between oral and 
intravenous tests between 120 and 240 min during which 
mean gliclazide concentrations were 563.5 ± 58.3 ng/mL 
and 625.4 ± 67.1 ng/mL (P = 0.06) for OGTT and IIGI, 
respectively.
Discussion
First, in a cohort of White British patients with type 2 dia-
betes on diet or metformin monotherapy, we have shown 
that low-dose gliclazide, resulting in drug concentrations 
far below those seen with normal “therapeutic” doses, sig-
nificantly reduces plasma glucose. Although low doses of 
gliclazide can be used successfully in patients with hepatic 
Table 2. Summary of phase 1 results by dose
10 mg gliclazide (n = 4) 20 mg gliclazide (n = 4)
 Control Gliclazide P-value Control Gliclazide P-value
Mean glucose from AUC (mmol/L) 11.7 ± 1.19 11.03 ± 1.47 0.36 11.3 ± 1.64 10.13 ± 1.45 0.02
Incretin effect insulin (%) 24.5 (7.0, 51.5) 27 (21.0, 32.3) >0.9 31.2 (14.4, 54.5) 56.0 (39.9, 72.8) 0.13
Incretin effect C-peptide (%) 11.3 (-10.6, 36.5) 18.3 (13.5, 20.4) 0.88 27.4 (15.0, 43.9) 23.7 (14.5, 48.3) 0.88
AUC glucagon (oral) (nmol l-1 min) 5.6 (5.1, 7.4) 5.5 (5.1, 7.0) 0.25 5.7 (4.7, 7.3) 6.0 (4.7, 7.8) 0.63
AUC glucagon (IV) (nmol l-1 min) 4.0 (3.5, 5.5) 4.1 (3.3, 5.8) 0.63 4.6 (4.4, 6.1) 4.5 (4.3, 9.8) 0.88
AUC total GLP-1 (nmol l-1 min) 1.1 (0.8, 1.5) 1.1 (0.8, 1.4) 0.88 0.7 (0.6, 1.4) 0.9 (0.7, 2.1) 0.25
AUC total GIP (nmol l-1 min) 13.1 (11.6, 14.8) 14.8 (12.3, 15.3) > 0.9 10.5 (5.3, 20.1) 9.4 (5.7, 24.4) 0.88
Glucose data presented as mean ± SEM. All other parameters are presented as median (lower quartile, upper quartile).
Table 3. Summary of incretin effect results from phase 2 
(n = 16)
Parameter Control Gliclazide P-value
Mean Glucose from  
AUC (mmol/l)
12.0 ± 0.56 10.8 ± 0.5 <0.01
Incretin Effect  
Insulin (%)
35.5 (27.3, 61.2) 55.0 (34.8, 72.8) <0.05
Incretin Effect  
C-Peptide (%)
28.4 (12.9, 47.0) 39.9 (17.9, 52.8) <0.05
Data for mean glucose from AUC are given as mean ± SEM. Data for incretin 
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nuclear factor 1α maturity-onset diabetes of the young 
due to extreme sulphonylurea sensitivity (22), only 1 other 
Japanese study in adult type 2 diabetes has been conducted 
that showed improvements in glycemic control with low-
dose gliclazide (23). However, this study did not assess 
acute physiological response to glucose load; in addition, 
although this study reported increased rates of hypogly-
cemia in the gliclazide cohort, this outcome was only as-
sessed on symptom reporting without recording of blood 
glucose.
Second, for the first time using low-dose gliclazide, we 
show that sulphonylureas augment the classical incretin 
effect in patients with type 2 diabetes, in addition to the 
known effects on glucose and insulin secretion. This mech-
anism has been suggested previously using therapeutic 
doses of glipizide and GIP infusion in hyperglycemic 
clamps; Aaboe et al showed that when 10 mg glipizide was 
administered prior to GIP infusion there was potential syn-
ergy between sulphonylurea and GIP (18). In our study, we 
used low-dose gliclazide and show augmentation of en-
dogenous incretin response in type 2 diabetes, suggesting 
a potential therapeutic use and novel mechanism for low-
dose sulphonylureas in patients with type 2 diabetes. This 
is supported as the slope of insulin secretion dependent on 
glucose was augmented in response to gliclazide interven-
tion following oral glucose but not intravenous glucose 
(Fig. 3). Furthermore, trendline prediction shows them to 
cross around the level of 5, suggesting that sulphonylureas 
at a low dose are unlikely to stimulate insulin secretion 
below this threshold. This is in contrast to high-dose 
sulphonylureas, which have been shown to dissociate the 
glucose dependency of GLP-1 (24). We show no impact 
of low-dose gliclazide on secretion of GLP-1, GIP, or glu-
cagon, all supporting a role for the triggering pathway to 
augment incretin action.
We hypothesized that low-dose sulphonylureas may 
work to increase incretin action with only minimal acti-
vation of the triggering pathway and, similar to the mech-
anism for glucose responsiveness in K
ATP-neonatal diabetes 
mellitus treated with sulphonylurea, conjectured that this 
would be due to a partial closure of KATP channels resulting 
in a rise in beta-cell membrane potential to a level where 
the incretin pathway may act. Although we have estab-
lished that low-dose gliclazide does indeed increase the 
incretin effect, the potential mechanisms that underlie such 
an effect remain unclear. We suggest a complex interaction 
of mechanisms, which, in addition to membrane electro-
physiology (25), may also include a role for intracellular 
calcium, which has been shown to control exocytosis by 
mediating emptying of immediately releasable pools (26). 
This is supported by the fact that low-dose sulphonylurea 
increased glucose sensitivity, a measure of the amplifying 
pathway, by 50% in response to intravenous glucose (ie, in 
the absence of increased incretins) (26).
Figure 2. Mean (SEM) plasma glucose (A) and gliclazide (B) and median 
(interquartile range) insulin (C) and C-peptide (D) concentrations during 
OGTT (solid lines) and IIGI (dashed lines) in control (red lines) and 
gliclazide intervention visits (blue lines) in phase 2 (n = 16). For inter-
ventions involving gliclazide (B), low-dose gliclazide suspension was 







/article/106/7/2036/6162832 by guest on 05 July 2021
The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 7 2043
An additional alternative mechanism from our analysis 
suggests that the increase in incretin effect observed with 
gliclazide treatment might be mediated by improvement of 
basal glucose as some studies suggest that glucose lowering 
partially restores the action of incretins (27), with height-
ened insulin response to supraphysiological GIP or GLP-1 
infusion noted following 4 weeks of intensive glucose 
lowering (28). However, in our study, the gliclazide is only 
given 1 h before the glucose stimulus so this mechanism 
seems unlikely.
This is the first study to report pharmacokinetic 
parameters of 20 mg gliclazide suspension. A single dose 
of 20 mg gliclazide suspension achieved CMAX of ~700 
ng/mL (Fig. 2B). This concentration following a single 
acute dose of gliclazide remained steady for the 4-h inter-
vention period in both oral and intravenous studies. For 
Table 4. Summary of AUC results from phase 2 (n = 16)
Parameter Control Gliclazide P-value
AUC insulin (nmol l−1min−1)    
 OGTT 68.8 (48.5) 91.2 (84.9) 0.01
 IIGI 51.7 (29.7) 55.5 (37.2) 0.38
AUC C-peptide (nmol l−1min−1)    
 OGTT 566 (306) 609 (362) <0.01
 IIGI 448 (362) 528 (306) 0.19
AUC total GLP-1 (nmol l−1min−1) OGTT 1.04 (0.9, 1.5) 1.0 (0.7, 1.8) 0.25
AUC total GIP (nmol l−1min−1) OGTT 15.1 (9.1, 19.3) 13.6 (11.6, 19.9) 0.51
AUC glucagon (nmol l−1min−1)    
 OGTT 4.9 (4.5, 5.6) 4.6 (4.4, 5.8) 0.56
 IIGI 3.8 (3.3, 4.7) 3.8 (3.4, 4.5) 0.63
Results for insulin, C-peptide, and glucagon (OGTT and IIGI) and total GLP-1 and total GIP (OGTT only) are given as median (lower quartile, upper quartile).
Figure 3. Linear regression analysis of mean insulin secretion against mean plasma glucose levels from phase 2 (n = 16) shows insulin secretion to 
be significantly augmented in response to oral glucose load (A) compared to intravenous glucose (B) following the addition of low-dose gliclazide 
(blue lines) vs control (red lines). (A) Slope increased from 33.6 to 80.97 (P < 0.0001), and (B) slope increased from 13.63 to 25.2 (P < 0.01).
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comparison, a single dose of 40 to 120 mg immediate 
release gliclazide in tablet formulation achieves CMAX 
of 2200 and 8000 ng/mL, respectively, whereas 30 mg 
modified release gliclazide achieves CMAX ~800 ng/mL 
with a half-life of 15 h (29,30). Thus, the 20 mg dose 
given 1 h before the isoglycemic clamp study resulted 
in gliclazide concentrations far lower than seen with 
normal therapeutic doses of the immediate release tablet 
formulations of gliclazide. It is interesting to note that 
the modified release formulation of gliclazide results in 
gliclazide concentrations more like those seen in our 
study. A 30-mg dose of modified release gliclazide, albeit 
with differing pharmacokinetic profile, is as effective at 
glucose lowering as 80 mg of immediate release gliclazide 
(30); our study suggests that some of the glycemic benefit 
of exposure to lower concentrations of gliclazide may be 
mediated by augmentation of incretin action. Consistent 
with this, modified release sulphonylureas are associated 
with lower risk of hypoglycemia when compared with 
standard release preparations such as glibenclamide/
glyburide (31) and glimepiride (32) and result in lower 
weight gain and slower time to failure compared with 
glibenclamide (33) and chlorpropamide (34). Further 
pharmacokinetic studies of low-dose gliclazide are 
ongoing.
This study has strengths in the use of the gold-
standard technique for physiological evaluation of the 
incretin effect and demonstrates results in line with ob-
servations from previous incretin physiology studies in 
type 2 diabetes (1,35). The main limitation of study is 
the wide variability in beta-cell response within a small 
sample size, which limits power and the ability to per-
form subanalyses; for example, the study is underpow-
ered to fully evaluate trends in phenotypes of responders. 
Furthermore, this study recruited only well-controlled 
type 2 diabetics; however, no difference was noted in re-
sponse dependent on HbA1c or duration of diabetes. The 
study design utilized open-label gliclazide, with modest 
glucose-lowering effect; therefore, a formal randomized 
controlled trial would be required to further evaluate 
these outcomes. Furthermore, the authors acknowledge 
the use of acute, not chronic, gliclazide dosing in this 
physiological study. The advantage of beta-cell modeling 
over classical incretin effect indices is the ability to model 
the time course of the incretin effect. It also accounts for 
possible small differences in glucose between OGTT and 
IIGI tests. However, as a more complicated procedure 
and by providing multiple parameters, it may add some 
estimation error. This would explain why significance 
is obtained with the classical indices but not with the 
model incretin potentiation AUC.
Conclusion
In this study we have shown that low-dose gliclazide re-
duces plasma glucose in response to oral glucose load, with 
concomitant augmentation of the classical incretin effect 
assessed by insulin and C-peptide secretion. In addition, 
modeling of beta-cell function shows that low plasma con-
centrations of gliclazide particularly potentiate late-phase 
Table 5. Summary of results from beta-cell modeling (mean ± SEM) from phase 2 (n = 16)
 Control Gliclazide P-value
Glucose sensitivity (pmol min-1m-2l mmol-1) 22.6 ± 3.94 33.1 ± 7.83 0.01
Rate sensitivity (pmol m−2 lmmol−1)    
 OGTT 265 ± 51.2 370 ± 137 >0.9
 IIGI 181 ± 51.2 119 ± 58.4 0.09
Incretin potentiation integral mean (AUC/time)    
 0-240 min 1.2 ± 0.05 1.3 ± 0.08 0.35
 180-210 min 0.92 ± 0.05 1.29 ± 0.14 0.04
Total insulin secretion rate (nmol/min−2)    
 OGTT 81.8 ± 9.1 99.7 ± 13.0 <0.01
 IIGI 68.3 ± 7.9 72.9 ± 7.6 0.27
Figure 5. Incretin potentiation profiles from 0 to 240 min for control 
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insulin secretion and increase glucose sensitivity by 50%. 
We propose that low-dose  sulphonylureas, with doses 
comparable, or lower than those seen with gliclazide modi-
fied release 30 mg, may result in effective glucose lowering 
with reduced risk of hypoglycemia. Given the low cost of 
sulphonylureas, trials of low-dose sulphonylureas in low- 
and middle-income countries are warranted.
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